Sugi Predict

Sugi Predict / Compounds / SCHEMBL29589609

SCHEMBL29589609

SCHEMBL29589609

Cc1ccc(C(NCCCC[C@H](NC(=O)[C@@H](NC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCN=[N+]=[N-])C(C)C)C(=O)Nc2ccc(CO[Si](c3ccccc3)(c3ccccc3)C(C)(C)C)cc2)(c2ccccc2)c2ccccc2)cc1

nearest known ligand 0.34

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
▸ SIRT2 Q8IXJ6 10/20 0.34
▸ SIRT1 Q96EB6 8/20 0.34
▸ FURIN P09958 4/20 0.34
▸ SIRT5 Q9NXA8 4/20 0.34
▸ SIRT3 Q9NTG7 3/20 0.33
▸ ALB P02768 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25358069 0.92 SIRT1 (0.35) SIRT2SIRT1SIRT5
SCHEMBL26015691 0.90 FURIN (0.37) SIRT2SIRT1FURINSIRT5SIRT3
SCHEMBL29048536 0.90 FURIN (0.37) SIRT2SIRT1FURINSIRT5SIRT3
SCHEMBL25383060 0.90 FURIN (0.37) SIRT2SIRT1FURINSIRT5SIRT3
SCHEMBL25361554 0.90 SIRT5 (0.38) SIRT2SIRT1FURINSIRT5SIRT3
SCHEMBL25361536 0.90 SIRT5 (0.38) SIRT2SIRT1FURINSIRT5SIRT3
SCHEMBL25361987 0.88 FURIN (0.37) SIRT2SIRT1FURINSIRT5ALB
SCHEMBL25361975 0.88 FURIN (0.37) SIRT2SIRT1FURINSIRT5ALB
SCHEMBL25361835 0.88 FURIN (0.34) SIRT2SIRT1FURINSIRT3ALB
SCHEMBL25350530 0.88 FURIN (0.35) SIRT2SIRT1FURINSIRT5SIRT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4237008-A2 CARRIER PARTICLE-DRUG CONJUGATES, SELF-IMMOLATIVE LINKERS, AND USES THEREOF Elucida Oncology, Inc. (US) 2023-09-06 — — EP disclosed
EP-4106820-A1 METHODS OF FUNCTIONALIZING NANOPARTICLES Elucida Oncology, Inc. (US) 2022-12-28 — — EP disclosed
EP-4103236-A1 FOLATE RECEPTOR TARGETED NANOPARTICLE DRUG CONJUGATES AND USES THEREOF Elucida Oncology, Inc. (US) 2022-12-21 — — EP disclosed
WO-2022093794-A9 METHODS OF FUNCTIONALIZING NANOPARTICLES ELUCIDA ONCOLOGY, INC. (US) 2022-06-09 — — WO disclosed
WO-2022093800-A2 CARRIER PARTICLE-DRUG CONJUGATES, SELF-IMMOLATIVE LINKERS, AND USES THEREOF ELUCIDA ONCOLOGY, INC. (US) 2022-05-05 — — WO disclosed
WO-2022093794-A1 METHODS OF FUNCTIONALIZING NANOPARTICLES ELUCIDA ONCOLOGY, INC. (US) 2022-05-05 — — WO disclosed
WO-2022093793-A1 FOLATE RECEPTOR TARGETED NANOPARTICLE DRUG CONJUGATES AND USES THEREOF ELUCIDA ONCOLOGY, INC. (US) 2022-05-05 — — WO disclosed
Send feedback